PDE4A and inflammatory bowel disease: Of note, although several clinical and molecular aspects distinguish CD from UC patients, these disorders shared many pro-inflammatory molecules; this aspect increases the probability that a small-molecule inhibitor of PDE4, such as apremilast, may be effective for the treatment of both forms of IBD.